<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099550</url>
  </required_header>
  <id_info>
    <org_study_id>PNUHEnMJMK1</org_study_id>
    <nct_id>NCT04099550</nct_id>
  </id_info>
  <brief_title>Effect of Real-time Continuous Glucose Monitoring System in Overweight or Obese Adults With Prediabetes</brief_title>
  <official_title>Effect of Real-time Continuous Glucose Monitoring System in Overweight or Obese Adults With Prediabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pusan National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In Korea, 5 million adults aged 30 years or older have diabetes. The development and
      expansion of Korea's economy and society, has led to dramatic chances in people's lifestyle
      and diet habits, and an increase in life expectancy. However, changes in lifestyle and diet
      habits related to the improvements of socioeconomic status may contribute to an increased
      diabetes burden in Korea. Therefore, it is important to prevent diabetes.

      The purpose of this study was to evaluate the effects of real time-continuous glucose
      measurement (RT-CGM) system compared to only lifestyle modification group on blood glucose,
      lipid profile and diabetes prevention in prediabetic adults with overweight or obesity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimising patient adherence to prescribed lifestyle interventions to achieve improved blood
      glucose control remains a challenge. Combined use of real-time continuous glucose monitoring
      (RT-CGM) systems may promote improved glycaemic control.

      Thirty adult with overweight or obesity and pre-diabetes are randomised to using either
      RT-CGM or self monitoring of blood glucose (SMBG) for 1 week with lifestyle intervention.

      After 3 month, outcomes were glycemic control (HbA1c, fasting glucose), weight, and lipid
      profile assessed pre- and post-intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 6, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>participants were randomised to undertake a 12-week lifestyle intervention with either RT-CGM or SMBG</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1C change</measure>
    <time_frame>Outcomes were assessed at baseline (week 0) and end of intervention (week 12)</time_frame>
    <description>All participants receive lifestyle intervention at week 0, week 4, and week 8. The intervention group was monitored initial 1 weeks with a RT-CGM and th control group continued self-monitoring blood glucose (SMBG) at least 2 times a day for 1 week.
HbA1c at baseline (week 0) and end of intervention (week 12).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight (Kg) change</measure>
    <time_frame>baseline (week 0) and end of intervention (week 12)</time_frame>
    <description>weight change (Kg) at baseline (week 0) and end of intervention (week 12)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lipid profile</measure>
    <time_frame>baseline (week 0) and end of intervention (week 12)</time_frame>
    <description>both groups were assessed fasting lipid profile (total cholesterol, triglyceride and HDL-cholesterol) at baseline (week 0) and end of intervention (week 12)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Continuous Glucose Monitoring</condition>
  <condition>Prediabetic State</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>SMBG with lifestyle intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All participants receive a 12-week lifestyle intervention (diet and exercise). The control group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RT-CGM with lifestyle intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants receive a 12-week lifestyle intervention (diet and exercise). The intervention group was monitored initial 1-week with a RT-CGM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RT-CGM</intervention_name>
    <description>The group was monitored blood glucose initial 1-week with a RT-CGM.</description>
    <arm_group_label>RT-CGM with lifestyle intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SMBG</intervention_name>
    <description>The group was monitored self-monitoring blood glucose (SMBG) at least 2 times a day for initial 1-week.</description>
    <arm_group_label>SMBG with lifestyle intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ BMI 23 kg/m2

          -  impaired fasting glucose (fasting glucose 100 to 125 mg/dL) or impaired glucose
             tolerance (2-h plasma glucose during oral glucose tolerance test (OGTT) 140 - 199
             mg/dl) or HbA1c 5.7% to 6.4%

        Exclusion Criteria:

          -  type 1 diabetes or type 2 diabetes or undergoing treatment for diabetes

          -  clinical history including malignancy

          -  fast history of cardiovascular disease (e.g. myocardial infarction, stroke), surgery,
             and trauma which may affect blood glucose within last 6 months

          -  taking medication (e.g. glucocorticoid, antipsychotics, anticholinergic drug etc.)
             which affect blood glucose

          -  acute infection within last 1 month

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JEONG MI KIM, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JEONG MI KIM, M.D</last_name>
    <phone>82-10-9431-3733</phone>
    <email>marse007@hanmail.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jeong Mi Kim</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong M Kim, MD</last_name>
      <phone>82-10-9431-3733</phone>
      <email>marse007@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.diabetes.or.kr/pro/news/admin.php?category=A&amp;code=admin&amp;number=1546&amp;mode=view</url>
    <description>Korean Diabetes Association: Diabetes fact sheet in Korea. 2018</description>
  </link>
  <reference>
    <citation>Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in Type 2 Diabetes--More Common Than You Think: A Continuous Glucose Monitoring Study. J Diabetes Sci Technol. 2015 Apr 27;9(5):999-1005. doi: 10.1177/1932296815581052.</citation>
    <PMID>25917335</PMID>
  </reference>
  <reference>
    <citation>Murphy HR, Rayman G, Lewis K, Kelly S, Johal B, Duffield K, Fowler D, Campbell PJ, Temple RC. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ. 2008 Sep 25;337:a1680. doi: 10.1136/bmj.a1680.</citation>
    <PMID>18818254</PMID>
  </reference>
  <reference>
    <citation>Tanenberg R, Bode B, Lane W, Levetan C, Mestman J, Harmel AP, Tobian J, Gross T, Mastrototaro J. Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial. Mayo Clin Proc. 2004 Dec;79(12):1521-6.</citation>
    <PMID>15595336</PMID>
  </reference>
  <reference>
    <citation>Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK. Continuous subcutaneous glucose monitoring in children with type 1 diabetes. Pediatrics. 2001 Feb;107(2):222-6.</citation>
    <PMID>11158450</PMID>
  </reference>
  <reference>
    <citation>Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001 Nov;24(11):1858-62.</citation>
    <PMID>11679447</PMID>
  </reference>
  <reference>
    <citation>Salkind SJ, Huizenga R, Fonda SJ, Walker MS, Vigersky RA. Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature. J Diabetes Sci Technol. 2014 Sep;8(5):1042-7. doi: 10.1177/1932296814537039. Epub 2014 May 29. Review.</citation>
    <PMID>24876453</PMID>
  </reference>
  <reference>
    <citation>Dagogo-Jack S, Egbuonu N, Edeoga C. Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk. Med Princ Pract. 2010;19(3):167-75. doi: 10.1159/000285280. Epub 2010 Mar 29. Review.</citation>
    <PMID>20357497</PMID>
  </reference>
  <reference>
    <citation>Hedayati SS, Elsayed EF, Reilly RF. Non-pharmacological aspects of blood pressure management: what are the data? Kidney Int. 2011 May;79(10):1061-70. doi: 10.1038/ki.2011.46. Epub 2011 Mar 9. Review.</citation>
    <PMID>21389976</PMID>
  </reference>
  <reference>
    <citation>LindstrÃ¶m J, Peltonen M, Eriksson JG, Ilanne-Parikka P, Aunola S, KeinÃ¤nen-Kiukaanniemi S, Uusitupa M, Tuomilehto J; Finnish Diabetes Prevention Study (DPS). Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia. 2013 Feb;56(2):284-93. doi: 10.1007/s00125-012-2752-5. Epub 2012 Oct 24.</citation>
    <PMID>23093136</PMID>
  </reference>
  <reference>
    <citation>MÃ¡rquez-Celedonio FG, TÃ©xon-FernÃ¡ndez O, ChÃ¡vez-Negrete A, HernÃ¡ndez-LÃ³pez S, MarÃ­n-RendÃ³n S, BerlÃ­n-Lascurain S. [Clinical effect of lifestyle modification on cardiovascular risk in prehypertensives: PREHIPER I study]. Rev Esp Cardiol. 2009 Jan;62(1):86-90. Spanish.</citation>
    <PMID>19150019</PMID>
  </reference>
  <reference>
    <citation>Yoon U, Kwok LL, Magkidis A. Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials. Metabolism. 2013 Feb;62(2):303-14. doi: 10.1016/j.metabol.2012.07.009. Epub 2012 Sep 7. Review.</citation>
    <PMID>22959500</PMID>
  </reference>
  <reference>
    <citation>Rosenberg K. Prediabetes Increases Risk of Cardiovascular Disease. Am J Nurs. 2017 Jun;117(6):71. doi: 10.1097/01.NAJ.0000520262.18448.1c.</citation>
    <PMID>28541998</PMID>
  </reference>
  <reference>
    <citation>Mayer-Davis EJ, Lawrence JM, Dabelea D, Divers J, Isom S, Dolan L, Imperatore G, Linder B, Marcovina S, Pettitt DJ, Pihoker C, Saydah S, Wagenknecht L; SEARCH for Diabetes in Youth Study. Incidence Trends of Type 1 and Type 2 Diabetes among Youths, 2002-2012. N Engl J Med. 2017 Apr 13;376(15):1419-1429. doi: 10.1056/NEJMoa1610187.</citation>
    <PMID>28402773</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pusan National University Hospital</investigator_affiliation>
    <investigator_full_name>JEONG MI KIM</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

